In other circumstances, such as in acute myelogenous leukemia (AML), the overexpression of MDM2, rather than a loss-of-function (LOF) mutation in P53, disrupts P53 function by ubiquitinating the protein and promoting its degradation and inactivation [11,12,13]. Here, MDM2 is linked to acute myeloid leukemia.